OBSV ObsEva 6-K2021ObsEva appoints David Renas as Chief Financial Officer
4 Jan 21
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
OBSV 6-K Filings
- 13 Jan 21 Current report (foreign)
- 11 Jan 21 ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
- 4 Jan 21 ObsEva appoints David Renas as Chief Financial Officer
- 10 Dec 20 Current report (foreign)
- 24 Nov 20 Current report (foreign)
- 16 Nov 20 ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…